Adicet Bio to Participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference
August 02 2023 - 4:00PM
Business Wire
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing allogeneic gamma delta T cell
therapies for cancer, today announced that Chen Schor, President
and Chief Executive Officer, will participate in a fireside chat at
the Canaccord Genuity 43rd Annual Growth Conference being held from
August 7-10, 2023 in Boston.
Details of the event are as follows: Date: Wednesday, August 9,
2023 Time: 1:00 p.m. ET
The live audio webcast can be accessed on the Investors section
of Adicet Bio’s website at https://www.adicetbio.com. An archived
replay will be available for 30 days following the
presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma
delta T cells, engineered with chimeric antigen receptors (CARs)
and chimeric antigen adaptors (CAds), to enhance selective tumor
targeting and facilitate innate and adaptive anti-tumor immune
response for durable activity in patients. For more information,
please visit our website at https://www.adicetbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230802947765/en/
Adicet Bio., Inc. Investor and Media Contacts
Anne Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Apr 2024 to May 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From May 2023 to May 2024